


TOP ↑
Industry
NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. IMS Health, Quintiles Agree to Merge

IMS Health Holdings, Inc., the pharmaceutical market information and technology provider, and Quintiles Transnational Holdings Inc., a contract research organization, have agreed to merge in a deal valued at approximately \$8.75 billion. The merged company will be named Quintiles IMS Holdings, Inc. [Read More](#)

2. Biogen to Spin Off Hemophilia Business

Biogen intends to spin off its hemophilia business as an independent, publicly traded company. The new company, to be named at a later date, will focus on the discovery and development of therapies for treating hemophilia, with existing marketed products to include Eloctate and Alprolix, indicated for treating hemophilia A and B, respectively. [Read More](#)

3. Former Ranbaxy Executives Lose Dispute to Daiichi Sankyo

The former sellers of shares of Ranbaxy Laboratories, which included RHC Holding Private Limited, have been ordered by an arbitration court to pay damages of 25.63 billion rupees (\$385 million) to Daiichi Sankyo Co Ltd. to settle a dispute regarding the acquisition of Ranbaxy by Daiichi. [Read More](#)

4. AMRI To Acquire Euticals for \$358 Million

AMRI, a global contract research and manufacturing organization, has agreed to acquire Euticals, a privately held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). The move is the latest in a series of acquisitions by AMRI and further enhances the company's custom synthesis and API manufacturing business, particularly in Europe. [Read More](#)

5. Allergan Gets FDA OK for Generic Version of AstraZeneca's Crestor

Allergan has received final FDA approval for its abbreviated new drug application for rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of AstraZeneca's anti-cholesterol drug, Crestor (rosuvastatin). For the 12 months ended March 31, 2016, Crestor had total US brand sales of approximately \$6.5 billion. [Read More](#)

6. New Merck KGaA CEO Takes the Helm

At its annual general meeting, Merck KGaA announced that following nine years as CEO of Merck KGaA, Karl-Ludwig Kley has handed over the position to Stefan Oschmann. [Read More](#)

7. Xellia Pharmaceuticals Enters Into FDA Modified Consent Decree

Xellia Pharmaceuticals, a specialty pharmaceutical company headquartered in Copenhagen, Denmark, has entered into a Modified Consent Decree with the FDA for its recently acquired facility in Cleveland, Ohio, the former facilities of Ben Venue Laboratories Inc. The modified decree sets out the process with which Xellia must comply to begin manufacturing at the site. Reaching an agreement with the FDA is an important step in the company's plan to resume operations in the new manufacturing units at the site. [Read More](#)

8. [EMD Serono To Expand R&D Facility in Massachusetts](#)

EMD Serono, the biopharmaceutical business of Merck KGaA, has announced a \$12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on innovation in R&D, with a focus on oncology, immuno-oncology, and immunology. [Read More](#)

9. [MilliporeSigma To Expand Viral Manufacturing Capacity](#)

MilliporeSigma plans to expand its Carlsbad, California facility to meet growing demand for viral and gene therapy products. Scheduled for completion in 2016, the Carlsbad campus will increase from 44,000 square feet to 65,000 square feet, with 16 modular viral bulk manufacturing cleanroom suites, two fill/finish suites, and twice the warehouse capacity. The Carlsbad facility is MilliporeSigma's flagship site for SAFC's viral and gene therapies offering. MilliporeSigma gained the facility through its \$17 billion acquisition of Sigma-Aldrich in 2015. [Read More](#)

10. [Colorcon Invests in New Film Coating Manufacturing Plant in Brazil](#)

Colorcon, an excipient manufacturer, is investing in a new film coating manufacturing plant in Indaiatuba - São Paulo State, Brazil. The construction is scheduled for completion by October 2016 with the production of commercial-scale product scheduled for January 2017. [Read More](#)

****Save the Date: DCAT Sharp Sourcing****

Mark your calendar for **Tuesday, July 12 for DCAT Sharp Sourcing**, the must-attend event for pharmaceutical companies, contract service providers and suppliers engaged in the pharmaceutical manufacturing value chain. This year's event will be held at the Hyatt Regency Hotel in New Brunswick, New Jersey and will feature solution-based practical insights from leading industry experts, specialized educational forums for buyers and suppliers, networking opportunities, and a special keynote speaker. Gain peer and customer insight on best practices and ways for optimizing your internal and external manufacturing and supply networks. Watch for announcements from DCAT for further details.

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org